CytomX Therapeutics, Inc. earnings per share and revenue
On 06 de nov. de 2025, CTMX reported earnings of -0.09 USD per share (EPS) for Q3 25, missing the estimate of -0.05 USD, resulting in a -74.42% surprise. Revenue reached 5.96 milhão, compared to an expected 11.86 milhão, with a -49.71% difference. The market reacted with a -13.60% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.06 USD, with revenue projected to reach 8.30 milhão USD, implying an diminuir of -33.33% EPS, and aumentar of 39.20% in Revenue from the last quarter.
FAQ
What were CytomX Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CytomX Therapeutics, Inc. reported EPS of -$0.09, missing estimates by -74.42%, and revenue of $5.96M, -49.71% below expectations.
How did the market react to CytomX Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -13.6%, changed from $4.19 before the earnings release to $3.62 the day after.
When is CytomX Therapeutics, Inc. expected to report next?
The next earning report is scheduled for 04 de mar. de 2026.
What are the forecasts for CytomX Therapeutics, Inc.'s next earnings report?
Based on 10
analistas, CytomX Therapeutics, Inc. is expected to report EPS of -$0.06 and revenue of $8.30M for Q4 2025.